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Abstract
Background: The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional
chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic
transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience
implementing EffTox in the Matchpoint trial.
Methods: EffTox is a Bayesian adaptive dose-finding trial design that jointly scrutinises binary efficacy and toxicity
outcomes. We describe a nomenclature for succinctly describing outcomes in phase I/II dose-finding trials. We use
dose-transition pathways, where doses are calculated for each feasible set of outcomes in future cohorts. We introduce
the phenomenon of dose ambivalence, where EffTox can recommend different doses after observing the same
outcomes. We also describe our experiences with outcome ambiguity, where the categorical evaluation of some
primary outcomes is temporarily delayed.
Results: We arrived at an EffTox parameterisation that is simulated to perform well over a range of scenarios. In
scenarios where dose ambivalence manifested, we were guided by the dose-transition pathways. This technique
facilitates planning, and also helped us overcome short-term outcome ambiguity.
Conclusions: EffTox is an efficient and powerful design, but not without its challenges. Joint phase I/II clinical trial
designs will likely become increasingly important in coming years as we further investigate non-cytotoxic treatments
and streamline the drug approval process. We hope this account of the problems we faced and the solutions we used
will help others implement this dose-finding clinical trial design.
Trial registration: Matchpoint was added to the European Clinical Trials Database (2012-005629-65) on 2013-12-30.
Keywords: EffTox, Phase I/II, Dose-finding, Efficacy, Toxicity, CML
Background
The introduction of BCR-ABL tyrosine kinase inhibitors
(TKIs; imatinib, dasatinib, nilotinib, bosutinib and pona-
tinib) has revolutionised the treatment of chronic myeloid
leukaemia (CML). The great majority of patients with
chronic phase (CP)-CML obtain a durable complete cyto-
genetic response and the rate of progression to blast phase
(BP) is 1 to 2% per annum in the first few years after
diagnosis, falling sharply when major molecular response
is obtained [1–3]. A minority of patients (<10%) present
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with de novo BP-CML and of these two-thirds are myeloid
and one-third lymphoid BP [4]. Despite the use of TKIs,
median survival after the diagnosis of BP-CML is between
6.5 and 11 months [5–8], with the majority of long-term
survivors being recipients of allogeneic stem cell trans-
plant in second CP [9]. This poor survival is often due
to patients developing new mutations, most frequently
within the BCR-ABL kinase domain, resulting in resis-
tance to TKIs and further rapid disease progression [10].
Therefore, novel therapies to improve and prolong thera-
peutic responses in BP-CML are urgently sought.
In the Matchpoint trial, we plan to simultaneously
assess co-primary safety and efficacy outcomes for the
combination of a novel TKI, ponatinib, with conven-
tional fludarabine, cytarabine and idarubicin (FLAG-IDA)
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chemotherapy. We believe this to be the first such study in
blastic phase CML. It is envisaged that the data will be the
first step to improve the treatment of this difficult clinical
problem.
The goal of this trial is to find the optimal dose of
ponatinib to combine with standard doses of FLAG-IDA,
rather than merely the maximum tolerable dose. In the
so-called cytostatic setting, dosing decisions should be
guided by patients’ outcomes with regard to efficacy and
toxicity, yielding designs for joint phase I/II trials. Differ-
ent statistical designs define dose optimality in different
ways. The method chosen in Matchpoint is described
below.
Published clinical trial designs in this arena include
extensions of the continual reassessment method [11]
(CRM). Braun’s bivariate CRM [12] models separate
toxicity and disease progression events. Zhang et al.’s
variant of CRM [13] called TriCRM uses an ordered tri-
nary outcome that incorporates response and toxicity.
More recently, Wages & Tait [14] introduced a method
that uses a latent CRM model to monitor toxicity and
selects amongst candidate efficacy models using Bayes
factors. Amongst non-CRM alternatives, Wang & Day
[15] detailed a utility-maximising approach that assumes
responses and toxicity occur in patients according to log-
normally distributed patient thresholds.
Thall & Cook [16] introduced EffTox, a Bayesian adap-
tive dose-finding design that models correlated binary
efficacy and toxicity outcomes. A search of PubMed on
17th October 2016 for articles that have cited Thall &
Cook [16] returned 54 items. Of these, 36 were method-
ological in nature, detailing extensions or alternative
designs. A further 14 were review articles. Only four
articles pertained to the design or reporting of a spe-
cific clinical trial. Three of these used the EffTox design
[17–19]. The first author is based at the MD Anderson
Cancer Center for two of these papers [17, 18], and at the
University of Washington for the third [19]. The fourth
trial article [20] cites the EffTox paper but uses a ran-
domised trial design. It is not our intention to give a full
systematic review but this scoping search suggests that
EffTox is not widely used, and scarcely used at all outside
the USA. Thall himself admitted that “[Bayesian models
for early phase clinical trials] have seen limited use in clin-
ical practice” [21]. In describing our experience using this
important dose-finding clinical trial design, we hope to
encourage others to use it too. Our proposed solutions to
the problems we encountered will expedite the trial design
process.
Methods
The EffTox design
Thall & Cook [16] introduced the adaptive Bayesian design
EffTox to facilitate seamless phase I/II dose-finding.
EffTox software is published by the MD Anderson
Cancer Center at https://biostatistics.mdanderson.org/
SoftwareDownload/. We use version 4.0.12.
EffTox uses logit models for the marginal probabilities
of efficacy and toxicity at each dose and utility contours
(n.b. the EffTox authors use the term desirability) to mea-
sure the attractiveness of each dose based on the posterior
probabilities of efficacy and toxicity.
Let y = (y1, . . . , yn) be the n doses under investigation.
Thall & Cook use the codified doses x = (x1, . . . , xn) such
that
xi = log yi −
n∑
j=1
log yj
n (1)
For example, a trial of 4 doses, 10mg, 20mg, 30mg
and 50mg, would have y = (10, 20, 30, 50), and x =
(−0.85,−0.16, 0.25, 0.76).
The marginal probabilities of efficacy and toxicity at
dose x are given by
logitπE(x, θ) = μE + βE,1x + βE,2x2 (2)
and
logitπT (x, θ) = μT + βTx (3)
When βT > 0, the toxicity probabilities increase mono-
tonically in dose. In contrast, the efficacy curve is not nec-
essarily monotonically increasing. The presence of βE,2
allows for non-linearity and a turning point.
The combined probability model is
πa,b = (πE)a(1 − πE)1−a(πT )b(1 − πT )1−b
+ (−1)a+b(πE)(1 − πE)(πT )(1 − πT )e
ψ − 1
eψ + 1
(4)
where ψ is an association parameter and (x, θ)-notation
has been suppressed in each function for brevity. Here,
a, b are binary patient-specific variables that denote
whether efficacy and toxicity events occurred. For a given
patient, a = 1 means the patient experienced efficacy and
b = 1 means they experienced toxicity.
The EffTox design requires several pieces of information
to be elicited from the investigators. Firstly, the statistician
must elicit the prior probability of efficacy and toxicity at
each dose. Let us label the vector of efficacy probabilities
ηE , and the toxicity analogue ηT . The EffTox software will
take these prior beliefs and a desired effective sample size
(ESS) and convert them into univariate normal priors on
each component of θ = (μT ,βT ,μE ,βE,1,βE,2,ψ). Thall
et al. [22] detail the algorithm and advise that ESS should
be between 0.5 and 1.5. High values for ESS reflect
stronger prior information. The preference is for priors
that are strong enough to sensibly guide early dosing
decisions but weak enough to be overridden by patient
outcomes where they diverge from prior beliefs.
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Secondly, the trialists must select parameters to cal-
culate the utility contours [16, 23]. The points
(
π∗1,E , 0
)
,
(
1,π∗2,T
)
and
(
π∗3,E ,π∗3,T
)
are selected such that they
are of equal utility. The quantity π∗1,E is the minimum
required probability of efficacy when toxicity is impossi-
ble. The quantity π∗2,T is the maximum permissible prob-
ability of toxicity when efficacy is guaranteed. The point(
π∗3,E ,π∗3,T
)
is chosen in the first quadrant (i.e. not lying
on the x- or y-axis), representing a point with equal attrac-
tiveness to the two other points. EffTox originally used
inverse quadratic functions to fit these points but after
observing some undesirable behaviour, the authors later
advocated using Lp norms [24]. An Lp norm is a mathe-
matical tool for generally measuring the distance between
two points. The best known is L2, the Euclidean norm,
that measures the length of a hypotenuse c in a right tri-
angle to satisfy c2 = a2 +b2, where a and b are the lengths
of the other two sides.
Thall et al. [22] stressed the importance of using con-
tours that are steep enough to encourage the design
to accept slightly higher probabilities of toxicity when
they are compensated with materially higher probabil-
ities of efficacy. This point was developed in detail in
Yuan et al. [25]. When the contours are too flat, patho-
logical behaviour can manifest where the design becomes
stuck at a sub-optimal dose. This point was unfortunately
missed in earlier publications on EffTox [16, 23]. Further-
more, the illustrative example in the original EffTox paper
[16] inadvertently uses a family of contours that exhibit
pathological behaviour. In order to achieve a design with
good properties, Thall advocates selecting three equiv-
alent points that yield a reasonably steep contour, and
not trying to elicit points of equal utility from clinicians
(please refer to reviewer comments). Fundamentally, trial-
ists should note that EffTox has evolved since its original
2004 publication [16].
The utility of a dose with associated posterior efficacy
and toxicity probabilities πE and πT is
u(πE ,πT ) = 1 −
((
1 − πE
1 − π∗1,E
)p
+
(
πT
π∗2,T
)p) 1p
(5)
In (5), p determines the extent of the curvature of the util-
ity contours. For p > 1, the contours are convex and for
p = 1, the contours are simply straight lines [24]. The
value for p is calculated by the EffTox software so that
the neutral utility curve intersects
(
π∗1,E , 0
)
,
(
1,π∗2,T
)
and
(
π∗3,E ,π∗3,T
)
.
EffTox uses decision criteria to determine the set of
admissible doses based on posterior beliefs. Given trial
data for j patients, D = {(x1, a1, b1), . . . , (xj, aj, bj)
}
, dose
x is admissible if
Pr
{
πE(x, θ) > πE|D
}
> pE (6)
and
Pr {πT (x, θ) < πT |D} > pT (7)
In order to resolve (6) and (7), a prior-to-posterior analysis
must be carried out to combine the investigators’ priors
with D. This involves solving a six-dimensional integral.
The details are given in Thall et al. [16].
The investigators provide values for πE , πT , pE and pT
in (6) and (7). The set of doses that are admissible is said
to be the admissible set. When a dose selection decision
is required (e.g. at the end of a cohort), the admissible set
is recalculated. If no dose is admissible, the trial stops and
no dose is selected for further research. This may occur
if all of the doses are too toxic or insufficiently effica-
cious, or both. If the admissible set is non-empty, the dose
with maximal utility, subject to rules about not skipping
untested doses, is recommended to be given to the next
cohort or patient.
This iterative process is repeated until the maximum
sample size or some pre-defined stopping criteria is
reached. The dose recommended after all patients have
been treated and evaluated is the dose selected for further
research in a later phase trial.
EffTox in the Matchpoint trial
We chose to use a seamless phase I/II dose-finding design
in Matchpoint because we wanted the efficacy events
observed to influence the doses selected. We chose to
use EffTox because of the readily-available MD Anderson
software with which to conduct the trial. Critically, the
software performs simulation studies, allowing trialists to
hone parameter choices. A summary of our parameter
choices appears in Table 1. These are discussed further
below.
In Matchpoint, the binary efficacy event is achieved
when patients experience at least a minor cytogenetic
response (i.e. <65% Philadelphia chromosome-positive
cells), or haematological response (platelets > 50×109/L,
neutrophils > 1.0 × 109/L and blasts < 5% in the
Table 1 EffTox parameters chosen in the Matchpoint trial. These
are discussed in the main text
Notation Interpretation Value
N Total number of patients 30
m Cohort size 3
pE Certainty required to infer dose is threshold efficable 0.03
pT Certainty required to infer dose is threshold tolerable 0.05
πE Minimum efficacy threshold 0.45
πT Maximum toxicity threshold 0.4
π∗1,E Required efficacy probability if toxicity is impossible 0.40
π∗2,T Permissible toxicity probability if efficacy guaranteed 0.70
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peripheral blood and bone marrow). The binary toxic-
ity outcome is defined by the occurrence of a range of
pre-specified adverse events, including any grade 3 or
4 clinically significant non-haematological adverse event,
related to ponatinib, that cannot be managed with optimal
medical care and likely to endanger the life of the patient
or result in long term effects. Both co-primary outcomes
are assessed over the eight week period following the com-
mencement of the first cycle of treatment. The first cycle
lasts for 28 to 56 days, depending on how long it takes for
blood counts to recover.
Of practical importance when using a seamless phase
I/II design is that the co-primary outcomes can be
assessed over a similar time horizon. It was felt that
responses to treatment could be expected after just one
cycle and that avoiding dose-limiting toxicity would be
instrumental to that. In a scenario where outcomes are
assessed over materially different horizons, the trial would
proceed at the speed determined by the outcome with
the longest assessment period and there would be an
increased risk of incomplete data, when one outcome is
assessed and the other is waiting to be assessed. This prob-
lem was ameliorated with the introduction of the Late
Onset EffTox design [26] but we do not use that design
here.
We investigate four doses of ponatinib: 15mg every
second day, 15mg daily, 30mg daily and 45mg daily, ref-
erenced as dose-levels 1, 2, 3, 4 respectively, as shown
in Table 2. For a tractable analysis, we use y =
(7.5, 15, 30, 45), and thus x = (−0.97,−0.27, 0.42, 0.82).
Generally, the clinicians were comfortable providing
their prior beliefs on the probability of efficacy and toxic-
ity. They believed a-priori that all doses would be tolera-
ble. There was some debate about the extent to which the
probability of efficacy would improve when moving from
the third to the highest dose. On balance, it was felt that
efficacy would be low at the lowest doses, increase with
dose throughout but begin to level-off at the highest dose.
This yielded the priors shown in Table 2.
The clinicians were also comfortable specifying πE and
πT . Conventional chemotherapy regimens like FLAG-
IDA can induce complete cytogenetic responses in
20–40% of patients who have progressed to blastic phase
Table 2 Doses under investigation in Matchpoint and the
investigators’ prior beliefs on rates of efficacy and toxicity
Dose-level Daily ponatinib dose (mg) Prior Pr(Eff), ηE Prior Pr(Tox), ηT
1 7.5 0.2 0.025
2 15 0.3 0.05
3 (start dose) 30 0.5 0.1
4 45 0.6 0.25
Note, the ponatinib dose labelled 7.5mg per day is actually 15mg every other day
[27]. Cortes et al. [28] gave 45mg of ponatinib daily
as a monotherapy to CML patients and observed major
cytogenetic response in 23% of 62 patients in blast trans-
formation phase. They also observed very good response
rates in chronic phase patients. By combining the treat-
ments, we hope to observe a response rate in excess of 45%
so we used πE = 0.45. It was our prior belief that only
the highest two doses would exceed the minimum efficacy
threshold. To achieve this level of efficacy, it was felt that
a toxicity rate up to 40% would be acceptable thus we set
πT = 0.40.
The first cohort will receive dose-level 3 (30mg) because
this is the lowest dose believed a-priori to be sufficiently
active. Compared to regular phase I trials, it may seem
aggressive to start a dose-finding trial at the third of four
doses. A typical phase I design would generally start at
a low dose and increase incrementally. Notably, there are
simultaneous objectives in dose-finding trials to avoid
both under- and over-dosing patients. Blastic transforma-
tion CML is an acute disease phase so there is a strong
motivation to avoid sub-therapeutic doses. The tolera-
bility of 45mg as monotherapy [28] led the clinicians to
believe that 30mg would be tolerable in combination.
From here, there is scope to escalate or de-escalate dose as
the outcomes dictate.
The values of pE and pT in (6) and (7) determine the pos-
terior confidence required to admit the doses as worthy
of investigation. Typically, low values are chosen so that
even relatively weak beliefs will render doses worthy of
investigation in this early phase clinical trial. For instance,
Thall et al. [22] use pE = pT = 0.1. We initially investi-
gated using the values pE = pT = 0.05 but later altered
this to pE = 0.03. The process of refining these values is
described in a later section [29, 30].
Rather than specify
(
π∗1,E , 0
)
and
(
1,π∗2,T
)
, we agreed
three points in the general efficacy-toxicity space (i.e. not
on the axes)
(
π∗3,E ,π∗3,T
)
,
(
π∗4,E ,π∗4,T
)
and
(
π∗5,E ,π∗5,T
)
such that the points had approximately equal utility.
We used the multi-variate solver multiroot in the
R [29] package rootSolve [30] to solve the simul-
taneous equations u
(
π∗3,E ,π∗3,T
)
= u
(
π∗4,E ,π∗4,T
)
=
u
(
π∗5,E ,π∗5,T
)
= 0. This yielded a neutral utility curve that
intersected (39.6%, 0%) and (100%, 67.9%). We rounded to
take π∗1,E = 0.40 and π∗2,T = 0.70, yielding p = 2.07. Our
family of contours are illustrated in Fig. 1. The contours
are quite steep where efficacy probabilities are less than
70%. We consider alternative contours in the discussion.
Finally, the value of ESS was chosen by trial-and-error.
Thall et al. [22] advise a value in the range (0.5, 1.5). If ESS
is too low, the prior can lead to pathological behaviour
of the design. Increasing ESS generally improves per-
formance in scenarios that broadly agree with the prior
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Fig. 1 Utility contours in the Matchpoint trial. The neutral utility contour in bold joins the points (0.4, 0), (0.5, 0.4) to (1.0, 0.7), represented by blue
triangles
beliefs, and vice-versa. Statisticians and investigators
should, however, be mindful of the necessity for the data
to override the prior in the event that the priors are wrong.
This advocates exercising caution when using inflated ESS
values. We arrived at ESS=1.3 because it yielded attrac-
tive simulated operating characteristics and sensible dose
transitions, as described in the following sections.
Nomenclature for describing outcomes in phase I/II trials
To expedite the discussion of phase I/II clinical trial con-
duct, we introduce our nomenclature. Each patient may
experience one of four specific outcomes: efficacy without
toxicity (E); toxicity without efficacy (T); both (B); or nei-
ther (N). Let us string these symbols behind a numerical
dose-level to denote the outcomes of cohorts of patients.
For instance, 2EET denotes a cohort of three patients that
were given dose-level 2, two of whom experienced effi-
cacy only and one who experienced toxicity. These strings
can be concatenated to describe the outcomes of several
cohorts consecutively. For example the path 2EET 3EBB
extends our previous scenario. After the first cohort, the
trial escalated to dose-level 3. The next cohort of three
were treated at this dose and all three patients experi-
enced efficacy. Unfortunately, two of them also experi-
enced toxicities. Using our notation, this information is
unambiguously conveyed in 8 characters.
In phase I/II, it is inadvisable to reduce patients’ out-
comes to simple tallies of efficacy and toxicity events
because of the complication that patients may experience
both events or neither. For instance, the design may rec-
ommend a different dose after observing NTE than it
would after observing NNB, even though both cohorts
contain a single efficacy event and a single toxicity event.
In the first example, the events are experienced by differ-
ent patients whereas in the latter, they are experienced by
the same patient. The distinction is especially pertinent in
EffTox because the ψ parameter models the association
between efficacy and toxicity.
The described notation combines simple codifica-
tion of dose-levels and patient outcomes to succinctly
and unambiguously describe pathways through phase
I/II dose-finding trials. We use it in the next section
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to define dose transition pathways, and in follow-
ing sections to discuss the potential problems of out-
come ambiguity and dose ambivalence, and to aid trial
planning.
Dose transition pathways
We found it greatly beneficial to prospectively analyse
how our dose-finding design would behave with respect
to cohorts by supposing each feasible set of future patient
outcomes and calculating the model advice in each. From
a given starting point, we look to identify the condi-
tions under which the design would escalate dose, stay
at a dose, de-escalate dose, or recommend that the trial
stops.
The principle of analysing dose-transition pathways
(DTPs) was introduced in a dose-finding trial [31] and has
been submitted for publication by Yap, et al. The exam-
ple in Table 3 shows the complete set of DTPs for cohort
2 having observed 3TTT in cohort 1 and de-escalating to
dose-level 2.
At dose-selection meetings in the Matchpoint trial, we
make frequent use of DTPs. We are particularly inter-
ested to learn the outcomes that would have to manifest
to change dose or stop the trial.
Table 3 After observing 3TTT in cohort 1, cohort 2 is
recommended to receive dose-level 2
Cohort 2 outcomes Dose for cohort 3
2NNN 3
2NNE 1
2NNT Stop trial
2NNB 1
2NEE 1
2NET 1
2NEB 1
2NTT Stop trial
2NTB 1
2NBB 1
2EEE 1
2EET 1
2EEB 1
2ETT 1
2ETB 1
2EBB 1
2TTT Stop trial
2TTB 1
2TBB 1
2BBB 1
The dose recommended for cohort 3 depends on the outcomes in cohort 2, as
depicted by these dose transition pathways
Dose decisions by EffTox, as projected in advance by
DTPs, can sometimes seem counter-intuitive. This may
be because the admissibility criteria and utility contours
work in unison to: a) filter out doses believed to be too
toxic or insufficiently active; and b) identify the most
desirable of the admissible doses. This particularly could
be the case relatively early in the trial stages when only a
small amount of discrete data is available.
Table 3 shows DTPs for a single future cohort but that
need not be a constraint. We use DTPs in Matchpoint to
analyse every feasible outcome of the next few cohorts.
DTPs can be calculated for several subsequent cohorts,
or even an entire trial. However, the number of possi-
ble paths grows geometrically with the number of cohorts
being considered. Each evaluable patient will experience
exactly one of E, T, N or B, independent of the other
patients. With cohorts of three, the number of distinct
outcomes for a single cohort is 20, as shown in Table 3,
hence the number of feasible DTPs for the next two and
three cohorts are 202 and 203 respectively. Thus, the lim-
itation of what can be depicted on printed pages tends
to limit our DTP analysis to no more than the next two
cohorts of three patients.
The DTPs tutorial in the clintrials package can be
used to reproduce Table 3. Refer to theAvailability of data
and software section at the end of this article.
Posterior utility
Thall & Cook work with utility as a function of the mean
posterior efficacy and toxicity probabilities of the doses. In
contrast, we consider the posterior distribution of utility
scores. For example, the posterior mean utility of dose x is
uˆ(πE ,πT )|D) =
∫
u(πE ,πT )L(θ |D)f (θ)dθ∫ L(θ |D)f (θ)dθ (8)
where L is the likelihood function given in EffTox [16],
f (θ) is the parameter prior distribution, and πE and πT are
shorthand for πE(x, θ) and πT (x, θ) respectively.
The Utility tutorial in the clintrials package shows
how to calculate posterior plots of utility like those in
Figs. 2 and 3. Refer to the Availability of data and software
section at the end of this article.
Results
In this section we describe some problems we encoun-
tered and the practical solutions we implemented using
the methods described in the previous section. All data in
this section are hypothetical or simulated. No actual trial
outcomes are presented.
Outcome ambiguity
Patients in the blastic transformation phase of CML under
study in the Matchpoint trial are particularly sick. The
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Fig. 2 Posterior utility after 3 patients. Posterior densities of the utility of doses 3 and 4. After three patients with outcomes 3NTE, the densities
largely occupy the same space and dose ambivalence is likely
Fig. 3 Posterior utility after 15 patients. Posterior densities of the utility of doses 3 and 4. In contrast to Fig. 2, after 15 patients with outcomes 2NNN
3ENN 4EBE 3TEE 4NEE, the posterior utilities are quite distinct and dose ambivalence is much less likely
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FLAG-IDA regimen is toxic and the addition of pona-
tinib only increases the potential for adverse events. Peri-
odic dose-selection meetings are a feature of dose-finding
studies, where early safety and efficacy outcomes are
reviewed and a new dose for the next patient or cohort
is selected. Sometimes, because of the frail nature of the
patients, efficacy assessments are temporarily delayed.
This outcome ambiguity presents a challenge for dose-
selection because the decision seemingly requires that full
patient outcomes be available. However, we have already
seen that this is not necessarily the case. In the scenario
depicted in Table 3, we know that at least one E or B event
in cohort 2 is enough to know with certainty that the trial
will proceed to cohort 3 using dose-level 1. If one of the
patients experiences E or B in cohort 2, the dose-decision
is independent of the other two patients so it does not
matter, purely from a dose-decision perspective, if some
of the outcome information is temporarily missing for the
other patients in cohort 2.
Naturally, this phenomenon does not always occur and
there are many occasions when every patient’s outcomes
will be required promptly to know the course of action
in the subsequent cohort. Furthermore, it is important
that outcomes for cohort 2 are finalised before trying to
establish doses for cohorts after cohort 3, for example,
because all patient outcomes affect the dosing decision in
model-based dose-finding designs. The describedmethod
merely offers short-term respite in some occasions if a
small number of data-points are temporarilymissing.
The general problem of partially observed outcomes has
been addressed more formally by Jin et al. [26] with their
Late Onset EffTox (LO-ET) design. This method incorpo-
rates time-to-event data and uses the predictive posterior
distribution of treated yet non-assessed patients to speed
up the trial.
Dose ambivalence
The probability model uses six parameters for which prior
distributions are stipulated. After patient outcomes are
observed, posterior estimates of efficacy and toxicity come
from evaluating a six-dimensional integral, one dimen-
sion for each parameter. Such integrals are approximated
numerically rather than solved analytically and this leads
to estimation error. Typically, early phase clinical trials do
not use a large number of patients so the amount of infor-
mation in the trial will usually be quite low, i.e. the number
of patients divided by the number of parameters being
estimated will be lower than a typical phase II or III trial.
The combined effect of these two sources of variability is
that the outputs of the EffTox model are subject to quite a
lot of uncertainty, especially in early cohorts.
This uncertainty is a feature of all sequentially adaptive
clinical trial designs that must rely on small to moderate
sample sizes. For instance, Thall et al. [32] demonstrate
in their Fig. 2 the uncertainty present in posterior utility
estimates of two-agent dose combinations after n = 60
patients.
An occasional unwelcome consequence of this uncer-
tainty in EffTox is that the model can occasionally
make different dose recommendations based on the same
patient outcomes. This is obviously undesirable in a clin-
ical trial where a categorical course of action is sought.
In Matchpoint, we referred to this phenomenon as dose
ambivalence. We noticed this whilst analysing DTPs.
The posterior utility density curve in Fig. 2 demon-
strates the difficulty a utility-maximising design like
EffTox faces when few patient outcomes have been
observed and two doses have very similar utility scores.
It shows the posterior beliefs on the utilities of dose-
levels 3 and 4 after observing 3NTE in cohort 1. For
clarity in illustration, dose-levels 1 and 2 are not shown.
The posterior curves are estimated using Monte Carlo
integration, bootstrap sampling and density smoothing
via the ggplot function in R [29]. Figure 2 shows that
the distribution for dose 4 has slightly greater variabil-
ity but that the two utilities have approximately equal
mean and mode. When the posterior utilities for the two
doses are so similar, it is difficult for the design to reliably
choose between them and dose ambivalence is the likely
result. After observing outcomes 3NTE in the first cohort,
the design sometimes recommends dose-level 3 for the
next cohort, and sometimes dose-level 4. This ambigu-
ity manifests because the two doses are both admissible,
have similar utility scores, and the Bayesian update inte-
gral is imperfectly calculated. This happens when using
the MD Anderson implementation of the EffTox software
that uses the spherical radial method of Monahan and
Genz [33] to estimate the posterior integrals, and our own
implementation in clintrials that uses Monte Carlo
integration.
It is possible to calculate the integral more precisely by
increasing the number of points in the numerical algo-
rithm but this risks missing an important message. If the
dose-recommendation is not consistent when calculated
to a reasonable numerical precision, the design is telling
us that it is difficult to pick between the doses. It could be
that several doses have similar utility scores, as we have
seen. Alternatively, it could be that a dose is very close to
the boundary for inclusion in the admissible set and its
eligibility determines the immediately preferable course.
Figure 3 shows similar curves after 15 patients with out-
comes 2NNN 3ENN 4EBE 3TEE 4NEE. In contrast, the
posterior utilities are now quite distinct and a consistent
dose decision is almost guaranteed.
During dose-update decisions, we ran the dose selection
decision multiple times to identify if dose ambivalence
was present. When it did manifest, we used posterior util-
ity plots like Figs. 2 and 3 and the view of independent
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clinicians and statisticians on the Matchpoint steering
committee to support decision-making.
The Ambivalence tutorial in the clintrials package
presents a Matchpoint scenario with dose ambivalence
and demonstrates repeated calculation of the dose-
decision. Refer to the Availability of data and software
section at the end of this article.
Changing pE to avoid premature stopping
In this section, we describe an unintended flaw in the
original parameterisation of our Matchpoint design that
lead to premature stopping. This undesirable behaviour
was uncovered by analysing DTPs. We advise trialists
to prospectively analyse DTPs of the early trial cohorts
yielded by candidate designs before starting the trial.
We commenced Matchpoint with both pE and pT set to
0.05 so that the design only had to be at least 5% sure that a
dose was efficacious and safe to include it in the admissible
set. These values are lower than those used conventionally.
Thall et al. [22] for example use pE = pT = 0.1. However,
we had cause to reduce pE further to 0.03 in Matchpoint.
Output from the official EffTox software in Table 4 reveals
the cause.
Having observed 3TTT in the first cohort, all doses
are believed to be unattractive. The most attractive dose
is actually dose-level 1, so the design would like to de-
escalate. However, the design cannot go straight to dose-
level 1 because the restriction to not skip untried doses
requires that dose-level 2 is tested first. The software does
not allow this feature to be turned off. However, with
pE = 0.05, dose-level 2 is actually inadmissible so the
design cannot de-escalate.
The problem is potentially exacerbated by the fact that
Pr(πT < πT ) is very close to the value pT = 0.05 for dose-
level 3. If this probability is estimated to be slightly less
than 0.05, as is plausible with just 3 data-points and a six-
dimensional Bayesian integral solved numerically, then
dose-level 3 becomes inadmissible also. Under these cir-
cumstances, with dose-level 4 inadmissible too on account
of excess toxicity, the design cannot recommend a dose so
it advocates stopping. This occurs in amaterial percentage
of the dose decision invocations using the EffTox software.
Using pE = pt = 0.1 further exacerbates the problem,
stopping categorically after 3TTT and 3NTT.
Observing three toxicities in the first three patients is
clearly a grave situation. However, we should be mindful
of the play of chance and the extent of our knowledge on
the event rates. The lower bound of the 95% confidence
interval for a binomial proportion having observed three
events in three trials is 29.2% using the exact method,
and 43.9% using the Wilson method. Hence, the true
toxicity rate could plausibly be much lower than the
100% rate observed with 3TTT. Also, we have no direct
knowledge of the toxicity rates at the other dose-levels,
only the information extrapolated by our model from the
toxicities observed at dose-level 3. We prefer that the
design be able to de-escalate after observing 3TTT and
the trial continue. We achieved this by reducing pE . We
advise fellow trialists to study DTPs routinely, especially
in early cohorts, to spot similar behaviour. When doing
so, as we have illustrated here, it is important to con-
sider the interaction of the contours and the admissibility
criteria [34].
Operating characteristics
Once a complete set of parameters has been proposed, we
learn how the design performs on average by simulation.
Blastic transformation phase CML is relatively rare. It
was felt that 30 patients was the upper feasible limit to
recruit in a reasonable time frame.We selected the highest
feasible sample size to maximise our chances of identify-
ing the optimal dose. Thirty patients would be sufficient
to offer the attractive operating characteristics discussed
below. We planned to use cohorts of three because this
would offer an attractive balance between the frequency of
model updates and opportunity for the design to explore
the doses.
The EffTox software provides the ability to simulate the
outcome of thousands of trials using the chosen design
and some assumed true efficacy and toxicity curves. In
practice, of course, the true curves are unknown. We
choose a variety of scenarios for simulation that will pro-
vide pertinent information on the behaviour of the design
in real usage.
Trialists should assess performance in a set of clinically
relevant scenarios. One of the scenarios should closely
resemble the investigators’ prior beliefs, as this represents
the anticipated outcome. We would expect the model to
Table 4 EffTox posterior beliefs after 3TTT
Dose 1 Dose 2 Dose 3 Dose 4
Utility -0.489 -0.534 -0.777 -0.817
Pr(πE > πE ) 0.079 0.037 0.060 0.200
Pr(πT < πT ) 0.919 0.758 0.051 0.005
Admissible under pE = 0.05, pT = 0.05 1 0 1 0
Admissible under pE = 0.03, pT = 0.05 1 1 1 0
The values for pE and pT determine the admissible doses
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Table 5 Operating characteristics of EffTox designs with 30 patients in cohorts of 3 and ESS=0.5, 1.3 and 1.5
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Stop
Pr(Eff) 0.20 0.30 0.50 0.60
1: Pr(Tox) 0.03 0.05 0.10 0.30
monotonic, Utility -0.33 -0.17 0.16 0.22
dose 4 ESS=0.5 0.01 0.01 0.34 0.63 0.01
optimal ESS=1.3 <0.01 <0.01 0.22 0.76 <0.01
ESS=1.5 <0.01 <0.01 0.22 0.77 <0.01
Pr(Eff) 0.40 0.60 0.75 0.79
2: Pr(Tox) 0.10 0.25 0.55 0.60
monotonic, Utility -0.01 0.25 0.12 0.08
dose 2 ESS=0.5 0.06 0.59 0.32 <0.01 0.03
optimal ESS=1.3 0.03 0.60 0.35 <0.01 0.01
ESS=1.5 0.03 0.57 0.39 <0.01 0.01
Pr(Eff) 0.25 0.40 0.60 0.60
3: Pr(Tox) 0.10 0.20 0.38 0.42
eff. plateau, Utility -0.26 0.04 0.15 0.12
dose 3 ESS=0.5 0.03 0.10 0.70 0.13 0.04
optimal ESS=1.3 0.01 0.10 0.73 0.13 0.02
ESS=1.5 0.01 0.09 0.73 0.15 0.02
Pr(Eff) 0.50 0.60 0.70 0.80
4: Pr(Tox) 0.20 0.20 0.20 0.20
tox. plateau, Utility 0.12 0.28 0.43 0.57
dose 4 ESS=0.5 0.02 0.03 0.61 0.34 <0.01
optimal ESS=1.3 <0.01 0.02 0.47 0.50 <0.01
ESS=1.5 <0.01 0.01 0.47 0.51 <0.01
Pr(Eff) 0.05 0.08 0.20 0.25
Pr(Tox) 0.05 0.08 0.12 0.14
5: Utility -0.58 -0.54 -0.34 -0.26
all doses ESS=0.5 0.06 0.03 0.01 0.37 0.53
inactive ESS=1.3 0.06 0.07 0.02 0.34 0.51
ESS=1.5 0.07 0.08 0.02 0.36 0.48
Pr(Eff) 0.05 0.08 0.12 0.25
6: Pr(Tox) 0.60 0.65 0.70 0.80
all doses Utility -0.78 -0.78 -0.76 -0.67
too toxic ESS=0.5 0.09 0.01 0.01 0.01 0.88
and inactive ESS=1.3 0.06 0.01 0.01 0.01 0.91
ESS=1.5 0.04 0.01 0.01 0.01 0.93
In Matchpoint, we use the model with ESS=1.3. In each scenario section, the probabilities of efficacy and toxicity are given, in addition to the utility scores determined by (5).
Dose i is the probability that dose-level i is recommended for further research, for i = 1, . . . , 4. Stop is the probability of stopping and recommending no dose. In rows
pertaining to design performance, the correct decision is in bold and the admissible decisions are underlined. When stopping is the correct decision, stopping is the only
admissible decision. The EffTox software gives selection probabilities to the nearest whole percent
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perform very well here. The setting for any clinical trial
is that we are unsure of the truth so the range of sce-
narios in which our design performs well should reflect
our ignorance. We considered how the design would per-
form if adverse circumstances prevailed. To these ends,
we advocate analysing performance when (i) no doses are
tolerable, and (ii) no doses are efficacious. In these sce-
narios, the desirable behaviour is to stop. As the clinical
scenario dictates, we might also advocate analysing sce-
narios where the true efficacy and toxicity curves are not
monotonically increasing.
In Table 5 we analyse in six indicative scenarios the
performance of our chosen EffTox model in Matchpoint,
labelled ESS=1.3. We have also given the performance of
two other models with priors on θ recalibrated using the
EffTox software to give ESS set to 0.5 and 1.5, being the
recommended lower and upper limits on ESS advised by
Thall et al. [22]. These convey the feasible range of per-
formance, holding all other parameters constant. In every
other regard, the three models are exactly the same.
We naturally seek a design that selects the optimal dose
most reliably. Our ESS=1.3 design with 30 patients makes
the optimal decision with probability at least 50% in each
scenario. In scenarios 1, 3 and 6, it makes the optimal
choice in the great majority of iterations.
Scenarios 1 and 4 show the benefit of a modestly more
informative prior. Through the addition of prior informa-
tion approximately equivalent to one patient (i.e. increas-
ing the effective sample size of the prior from 0.5 to 1.3
or 1.5), the probability that the design selects the optimal
dose is increased by up to 17%. Investigators will natu-
rally ponder the existence of the opposite effect, i.e. an
increased propensity to do the wrong thing when the pre-
vailing scenario disagrees with the prior. Scenario 3 shows
that this is not necessarily the case. The designs with
more informative priors actually perform slightly better,
despite a shape of efficacy curve that disagrees with the
prior.
Table 6 shows the mean probability that each design
variant identifies the optimal decision, given the six sce-
narios in Table 5. We see that our design is the superior of
the three presented. The variant with ESS=0.5 has inferior
performance, mostly for the reasons discussed. The vari-
ant with ESS=1.5 is only modestly inferior but provides no
reason to be preferred to our design.
We investigated by simulation the larger sample size
n = 60. The extra patients greatly improve performance in
some scenarios. In scenario 2, the probability of selecting
dose 2 increases by 20 to 80%. Similarly, the chances
of correctly stopping early in scenario 5 increase by 27
to 78%. In many clinical scenarios, recruiting a higher
number of patients is warranted in a phase I-II trial
because of the associated improvement in performance
and the presence of efficacy assessment that may abrogate
Table 6 Mean probabilities of performing the optimal decision
in the scenarios presented in Table 5
Design variant Mean Pr(Optimal decision)
ESS=0.5 0.612
ESS=1.3 0.668
ESS=1.5 0.65
a further traditional phase II trial. Phase I-II trials are
an opportunity to optimise the delivery of a new agent.
In the Matchpoint scenario, unfortunately, higher recruit-
ment was simply not feasible because of the rarity of
BP-CML.
We also investigated the impact of using pE = pT = 0.1.
The chances of stopping in scenario 5 are improved by
30%. As expected, the reciprocal effect is that the design
stops slightly more frequently in scenarios like 3 where an
optimal dose exists.
As well as their propensity to make the correct decision,
we also discriminate designs on how they allocate doses to
patients. A design that always makes the correct decision
but treats every patient at an over dose would not desir-
able, or indeed ethical. Table 7 gives the mean number of
patients allocated to each dose in the scenarios presented
in Table 5.
Of the three designs presented, our chosen design uses
the fewest patients in scenarios 5 and 6, where the correct
decision is to stop the trial. On the four remaining sce-
narios, our chosen design allocates the most patients on
average to the optimal dose in two scenarios. We see this
as further reason to prefer the design with ESS=1.3.
In summary, we have shown by simulation that our
selected EffTox parameterisation performs well in six sce-
narios. We have demonstrated that it stops reliably in
situations where all doses are too toxic or inefficacious.
We have also shown it to perform well in a scenario that
broadly matches our prior, and in scenarios that depart
from our prior. Lastly, we have demonstrated that our cho-
sen parameterisation with effective sample size set to 1.3
is superior to alternatives with ESS set to 0.5 and 1.5, in
terms of the probability of making the correct decision,
and in the allocation of patients to favourable doses.
Discussion
Finalising an EffTox design is generally an iterative
process. The inferences from analysing dose transition
pathways and simulations will naturally lead to re-
parameterisation and further testing. It is our general
preference to first hone the dose transitions. For the rea-
sons described, we pay particular attention to the earliest
circumstances under which the trial would stop. The
investigators should agree that these circumstances are
dire enough to warrant closing the trial. We also look
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Table 7 Numbers of patients allocated to doses in the six scenarios and three EffTox variants presented in Table 5
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Sum
1: Pr(Eff) 0.20 0.30 0.50 0.60
monotonic, Pr(Tox) 0.03 0.05 0.10 0.30
dose 4 Utility -0.33 -0.17 0.16 0.22
optimal ESS=0.5 0.7 0.6 12.1 16.4 29.8
ESS=1.3 0.2 0.2 9.8 19.6 29.8
ESS=1.5 0.1 0.1 9.5 20.1 29.8
2: Pr(Eff) 0.40 0.60 0.75 0.79
monotonic, Pr(Tox) 0.10 0.25 0.55 0.60
dose 2 Utility -0.01 0.25 0.12 0.08
optimal ESS=0.5 1.5 11.5 16.0 0.4 29.4
ESS=1.3 0.8 11.6 16.9 0.6 29.9
ESS=1.5 0.7 10.3 18.2 0.7 29.9
3: Pr(Eff) 0.25 0.40 0.60 0.60
eff. plateau, Pr(Tox) 0.10 0.20 0.38 0.42
dose 3 Utility -0.26 -0.04 0.15 0.11
optimal ESS=0.5 1.1 2.8 21.8 3.7 29.4
ESS=1.3 0.5 2.5 22.2 4.4 29.6
ESS=1.5 0.4 2.0 22.1 5.2 29.7
4: Pr(Eff) 0.50 0.60 0.70 0.80
tox. plateau, Pr(Tox) 0.20 0.20 0.20 0.20
dose 4 Utility 0.12 0.28 0.43 0.57
optimal ESS=0.5 0.5 1.0 19.3 9.2 30.0
ESS=1.3 0.1 0.7 15.9 13.3 30.0
ESS=1.5 0.1 0.3 15.9 13.7 30.0
5: Pr(Eff) 0.05 0.08 0.20 0.25
all doses Pr(Tox) 0.05 0.08 0.12 0.14
inactive Utility -0.58 -0.54 -0.34 -0.26
ESS=0.5 2.4 2.4 4.7 14.1 23.6
ESS=1.3 1.5 1.9 4.7 15.3 23.4
ESS=1.5 1.4 1.7 4.5 16.0 23.6
6 Pr(Eff) 0.05 0.08 0.12 0.25
all doses Pr(Tox) 0.60 0.65 0.70 0.80
too toxic Utility -0.78 -0.78 -0.76 -0.67
and inactive ESS=0.5 2.6 3.0 4.0 0.9 10.5
ESS=1.3 1.1 2.8 5.2 0.8 9.9
ESS=1.5 1.0 2.8 5.3 0.9 10.0
Dose i is the mean number of patients receiving dose-level i, for i = 1, . . . , 4. Row sums are also given in Sum. Sum = 30 in some instances due to trials stopping early.
Patients allocated to the optimal dose are given in bold and underlined for the admissible doses
for any sign that the design seems reluctant to select a
dose. This could suggest unsuitable priors or inappro-
priate parameter choices. It should be stressed, however,
that EffTox exists to guide our sequential selection of
doses based on patient outcomes. The trialists should
not stipulate every conceivable dose path and select
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parameters that replicate their choices. This approach
would preclude the use of a model at all. Rather, in our
opinion, the parameters should be selected for generally
acceptable behaviour, with due consideration given to the
extremes.
Once an acceptable parameterisation has been pro-
posed, the performance of the design should be assessed
by simulation under a broad range of scenarios. The
design should stop sufficiently early and reliably when all
doses are too toxic. In scenarios where optimal and/or
acceptable doses exist, the design should select those
with acceptable probability. Refinements to the param-
eterisation here will likely require the trial designer to
consider how they affect the behaviour of the design in
dose transition, and thus the circularity of the challenge is
illustrated.
We have considered even steeper contours, as stressed
by Thall et al. [22] and Yuan et al. [25]. They did not lead to
superior performance in the particular scenarios we have
chosen. This is likely due to the fact that our contours
are steep for efficacy probabilities as high as 70%, which
we consider to be the clinically plausible scenario in BP-
CML. However, the point remains that trade-off contours
should be steep to motivate the design to accept higher
probabilities of efficacy for acceptably higher probabilities
of toxicity.
EffTox is a powerful yet underused statistical design
for seamless phase I/II dose-finding clinical trials. Model-
based designs are becoming more important as trialists
and funders move away from so-called “up-and-down”
designs [35] like 3+3. This trend will be further driven
as investigators research treatments for which the
maximum-tolerated dose is unlikely to coincide with the
most effective dose. We have described the obstacles we
faced in implementing EffTox in Matchpoint and our
approach to overcoming those obstacles in the hope that
this will help trialists.
We were able to choose EffTox because our co-primary
outcomes efficacy and toxicity were assessed over a sim-
ilar time-frame. EffTox and other dose-finding designs
with co-primary outcomes would not have been suitable
if one had required a longer assessment period.
A key reason for selecting EffTox was the readily avail-
able, free software provided by the MD Anderson Cancer
Center for performing dose calculations and simulations
of trial operating characteristics. With the many time
pressures that come with working in an academic clin-
ical trials unit, it was a tremendous advantage to have
reliable software with which to design and run this
trial. One of the drawbacks of using compiled software
was our inability to alter or add certain behaviours. For
instance, we might have suppressed the no-skipping in
de-escalation rule, had that been possible. The desire
to routinely calculate dose-transition pathways led us
to develop an open-source implementation of EffTox in
clintrials [34].
Conclusion
Joint phase I/II clinical trials will likely become more
common in coming years as we investigate non-cytotoxic
treatments and streamline the drug approval process.
EffTox is an important trial design because it addresses
both of these needs. However, it requires parameterisa-
tion and preliminary calculation. Choices for parameters
can potentially have both intended and unintended con-
sequences. The process of finalising an EffTox design is
inherently iterative. We aim to help trialists implement
the design by describing our solutions to the problems we
faced.
We have discussed the parameters we chose and how
we selected them. We have stressed the need to look
at the dose transition pathways, particularly in the early
stages when few outcomes are observed, and at the cir-
cumstances that would lead to the trial’s termination. We
have highlighted the problem of dose ambivalence, illus-
trated graphically, and suggested a pragmatic solution.
We have described the problem of outcome ambiguity,
and how dose-transition pathways can mitigate the prob-
lem in the short term, allowing the dose-finding trial to
proceed whilst clinical evaluation is ongoing. Finally, we
have advised on the simulation scenarios that should be
considered. We hope this paper will help other investiga-
tors implement this important dose-finding clinical trial
design.
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